Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
GRTS

GRTS - Gritstone Oncology Inc Stock Price, Fair Value and News

0.83USD-0.01 (-1.19%)Market Closed

Market Summary

GRTS
USD0.83-0.01
Market Closed
-1.19%

GRTS Stock Price

View Fullscreen

GRTS RSI Chart

GRTS Valuation

Market Cap

91.2M

Price/Earnings (Trailing)

-0.63

Price/Sales (Trailing)

5.83

Price/Free Cashflow

-0.77

GRTS Price/Sales (Trailing)

GRTS Profitability

Return on Equity

-1.0K%

Return on Assets

-105.61%

Free Cashflow Yield

-129.68%

GRTS Fundamentals

GRTS Revenue

Revenue (TTM)

15.6M

Rev. Growth (Yr)

-28.69%

Rev. Growth (Qtr)

-83.22%

GRTS Earnings

Earnings (TTM)

-144.9M

Earnings Growth (Yr)

-18.89%

Earnings Growth (Qtr)

-31.09%

Breaking Down GRTS Revenue

52 Week Range

0.85
(Low)(High)

Last 7 days

12%

Last 30 days

12%

Last 90 days

-59.4%

Trailing 12 Months

-54.6%

How does GRTS drawdown profile look like?

GRTS Financial Health

Current Ratio

2

Debt/Equity

2.89

Debt/Cashflow

-2.85

GRTS Investor Care

Shares Dilution (1Y)

22.11%

Diluted EPS (TTM)

-1.24

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202415.6M000
202315.2M11.7M10.2M16.3M
202215.7M18.3M18.7M19.9M
202142.5M44.8M46.5M48.2M
20204.3M3.6M3.6M4.0M
20192.4M3.7M4.6M4.4M
20180001.2M

Tracking the Latest Insider Buys and Sells of Gritstone Oncology Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
May 16, 2024
jones erin
sold
-20,576
0.7483
-27,498
evp, chief operating officer
May 16, 2024
economides vassiliki
sold
-20,576
0.7483
-27,498
evp, chief financial officer
May 16, 2024
hawryluk matthew
sold
-13,857
0.7483
-18,518
evp, chief business officer
May 16, 2024
jooss karin
sold
-20,576
0.7483
-27,498
see remarks
May 16, 2024
allen andrew r
sold
-18,156
0.7483
-24,263
president and ceo

1–10 of 50

Which funds bought or sold GRTS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 17, 2024
Artal Group S.A.
new
-
2,649,550
2,649,550
0.07%
May 16, 2024
Tidal Investments LLC
new
-
63,058
63,058
-%
May 16, 2024
JANE STREET GROUP, LLC
reduced
-26.1
-28,282
381,722
-%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-37.25
-6,173
23,297
-%
May 15, 2024
DEUTSCHE BANK AG\
new
-
7,658,640
7,658,640
-%
May 15, 2024
STATE STREET CORP
added
1.08
993,461
4,626,710
-%
May 15, 2024
WELLINGTON MANAGEMENT GROUP LLP
new
-
850,873
850,873
-%
May 15, 2024
MORGAN STANLEY
added
22.13
6,064,930
17,326,700
-%
May 15, 2024
HSBC HOLDINGS PLC
new
-
26,458
26,458
-%
May 15, 2024
PRICE T ROWE ASSOCIATES INC /MD/
added
4.00
53,000
224,000
-%

1–10 of 43

Are Funds Buying or Selling GRTS?

Are funds buying GRTS calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own GRTS
No. of Funds

Unveiling Gritstone Oncology Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
point72 asset management, l.p.
4.2%
3,974,867
SC 13G/A
Feb 14, 2024
redmile group, llc
9.9%
10,135,388
SC 13G/A
Feb 13, 2024
frazier life sciences public fund, l.p.
0.0%
0
SC 13G/A
Feb 08, 2024
morgan stanley
5.8%
5,519,102
SC 13G
Jan 29, 2024
blackrock inc.
6.2%
5,868,353
SC 13G
Feb 14, 2023
frazier life sciences public fund, l.p.
5.0%
4,131,470
SC 13G/A
Feb 14, 2023
avidity partners management lp
3.3%
2,859,971
SC 13G/A
Feb 14, 2023
point72 asset management, l.p.
9.2%
7,679,867
SC 13G/A
Feb 14, 2023
redmile group, llc
9.9%
8,483,322
SC 13G/A
Feb 10, 2023
ecor1 capital, llc
0%
0
SC 13G/A

Recent SEC filings of Gritstone Oncology Inc

View All Filings
Date Filed Form Type Document
May 17, 2024
4
Insider Trading
May 17, 2024
4
Insider Trading
May 17, 2024
4
Insider Trading
May 17, 2024
4
Insider Trading
May 17, 2024
4
Insider Trading
May 17, 2024
4
Insider Trading
May 10, 2024
DEFA14A
DEFA14A
May 09, 2024
10-Q
Quarterly Report
May 09, 2024
8-K
Current Report
Apr 30, 2024
3
Insider Trading

Peers (Alternatives to Gritstone Oncology Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
62.6B
6.8B
56.39% 18.60%
-10.49
9.14
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
19.1B
2.0B
3.51% -21.34%
-57.48
9.53
75.20% 68.82%
14.5B
2.5B
-14.58% -16.90%
70.65
5.87
13.74% 186.89%
13.1B
3.8B
12.11% -10.56%
17.53
3.47
8.58% 129.81%
MID-CAP
5.5B
107.9M
16.79% 114.35%
-10.02
48.09
54.84% -28.31%
5.3B
524.1M
-8.42% -49.32%
-12.68
10.1
394.93% 39.61%
3.6B
251.0M
8.14% 7.06%
-12.31
14.53
73.58% -86.73%
3.1B
240.7M
5.18% -30.65%
-6.63
12.77
-1.03% -213.43%
2.6B
813.8M
-6.89% -38.06%
-1.5K
3.21
56.43% 98.83%
SMALL-CAP
2.2B
996.6M
286.24% 96.75%
-5.54
2.21
-26.66% 65.49%
1.9B
411.3M
6.95% 33.69%
29.29
4.64
60.38% -34.49%
482.9M
881.7K
19.87% 314.21%
-14.31
481.06
-77.61% 33.36%
293.3M
4.9M
12.97% 42.93%
-2.35
60.27
-54.97% 48.23%
19.2M
2.1M
25.28% 144.97%
-0.83
7.61
-13.45% 69.54%

Gritstone Oncology Inc News

Latest updates
TipRanks29 Apr 202411:33 am
Yahoo Finance04 Apr 202407:00 am

Gritstone Oncology Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue-83.2%1,74210,3821,5651,9552,4434,2623,0215,4717,1913,0642,6142,84339,6931,3489394881,2628849841,1501,347
Operating Expenses1.7%41,54340,85440,16937,68337,25936,18232,89835,13936,15432,84830,76928,00931,79728,49627,08126,54527,93329,19729,46823,36420,276
  S&GA Expenses-100.0%-7,9167,4066,7166,7456,7616,4627,7927,9556,6826,3735,9376,9415,6605,0315,2555,4655,6154,5824,8354,377
  R&D Expenses0.3%33,04132,93832,76330,96730,51443,52026,43627,347-26,16624,39622,07224,85622,83622,05021,29022,46823,58224,88618,52915,899
Interest Expenses6.5%1,2961,217991985844672551-24.00------------
Net Income-31.1%-40,400-30,818-38,434-35,256-33,982-31,290-29,966-29,515-28,916-29,769-28,118-25,1187,923-27,167-26,073-25,868-26,206-27,704-27,548-21,172-18,009
Net Income Margin-9.3%-9.26*-8.47*-13.59*-11.17*-8.21*-6.00*-6.30*-6.34*-7.12*-1.56*-1.56*-1.57*---------
Free Cashflow-70.8%-33,710-19,739-32,140-32,674-41,667-31,783-26,936-27,790-35,263-25,109-16,372-24,370---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-22.8%137178187223210241205214243278271224247222123146163184209228175
  Current Assets-40.7%52.0087.0091.0012215518315316219322121817720317574.0094.00112131155185135
    Cash Equivalents-22.3%49.0063.0030.0041.0047.0055.0077.0080.0084.0011114865.0010917159.0064.0056.0058.0011810936.00
  Net PPE-18.5%14.0017.0019.0020.0020.0021.0022.0023.0022.0022.0021.0022.0022.0022.0023.0025.0026.0027.0024.0019.0016.00
Liabilities-2.1%12312611311369.0070.0068.0051.0054.0062.0063.0045.0048.0055.0051.0049.0048.0050.0052.0046.0043.00
  Current Liabilities-5.4%26.0027.0023.0022.0025.0035.0032.0032.0034.0040.0036.0021.0022.0027.0022.0019.0018.0020.0023.0018.0014.00
  Long Term Debt0.5%40.0040.0030.0030.0030.0019.0019.00--------------
    LT Debt, Non Current-100.0%-40.0030.0030.0030.0019.0019.00--------------
Shareholder's Equity-73.1%14.0052.0074.0011014117113716318921620817919916772.0096.00115134156182132
  Retained Earnings-6.1%-699-659-628-590-555-521-489-459-430-401-371-343-318-326-299-273-247-221-193-165-144
  Additional Paid-In Capital0.4%714711703700696692627624620618580522518493371369363355350348277
Shares Outstanding0.5%98.0098.0093.0091.0088.0087.0086.0086.0086.0079.0078.0077.00---------
Float----174---172---419---199---277-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-71.7%-33,567-19,548-31,047-30,953-40,100-30,300-25,812-26,337-33,451-23,779-14,899-22,70010,700-25,202-20,200-20,723-22,977-22,400-25,100-18,373-19,127
  Share Based Compensation15.0%3,2462,8232,9642,9402,8913,0083,0643,3543,1312,7992,8192,7332,2011,6951,8391,9571,6191,4431,5321,3171,007
Cashflow From Investing-67.9%12,30338,29518,28124,59221,173-46,1523,07522,4797,634-46,62641,160-23,487-89,60011,61815,73223,82514,774-41,34933,98321,7771,430
Cashflow From Financing-102.4%-37915,717-2641,0178,64764,36519,340310-91732,87756,7431,74517,395125,43237.004,6775,6554,26725269,79086.00
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

GRTS Income Statement

2024-03-31
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Total revenues$ 1,742$ 2,443
Operating expenses:  
Research and development33,04130,514
General and administrative8,5026,745
Total operating expenses41,54337,259
Loss from operations(39,801)(34,816)
Interest income7121,678
Interest Expense(1,296)(844)
Net loss(40,385)(33,982)
Other comprehensive loss:  
Unrealized (loss) gain on marketable securities(4)28
Comprehensive loss$ (40,389)$ (33,954)
Net loss per share, basic$ (0.34)$ (0.3)
Net loss per share, diluted$ (0.34)$ (0.3)
Weighted-average number of shares used in computing net loss per share, basic118,391,224114,423,000
Weighted-average number of shares used in computing net loss per share, diluted118,391,224114,423,000
Collaboration and license revenues [Member]  
Total revenues$ 49$ 542
Grant Revenues [Member]  
Total revenues$ 1,693$ 1,901

GRTS Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 42,395$ 62,986
Marketable securities3,90816,288
Restricted cash1,2472,299
Prepaid expenses and other current assets4,3035,862
Total current assets51,85387,435
Long-term restricted cash5,2905,290
Property and equipment, net14,08817,281
Lease right-of-use assets65,05766,839
Deposits and other long-term assets924924
Total assets137,212177,769
Current liabilities:  
Accounts payable7,2483,819
Accrued compensation4,3409,357
Accrued liabilities2,1411,213
Accrued research and development expenses4,0453,696
Lease liabilities, current portion6,8116,904
Deferred revenue, current portion1,2852,350
Total current liabilities25,87027,339
Other liabilities, noncurrent907709
Lease liabilities, net of current portion56,14157,727
Debt, noncurrent40,33040,144
Total liabilities123,248125,919
Commitments and contingencies (Notes 6, 8 and 9)
Stockholders’ equity:  
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding at March 31, 2024 and December 31, 202300
Common stock, $0.0001 par value; 300,000,000 shares authorized at March 31, 2024 and December 31, 2023; 98,114,860 and 97,585,415 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively2222
Additional paid-in capital713,889711,386
Accumulated other comprehensive (loss) gain(1)3
Accumulated deficit(699,946)(659,561)
Total stockholders’ equity13,96451,850
Total liabilities and stockholders’ equity$ 137,212$ 177,769
GRTS
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, a neoantigen-based immunotherapy, which is in Phase 2/3 clinical trials for the treatment of solid tumors, including microsatellite stable colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors. In addition, it develops CORAL, a SARS-CoV-2 vaccine platform designed to deliver spike and additional SARS-CoV-2 T cell epitopes for protection and broader immunity against SARS-CoV-2 variants; and a therapeutic vaccine candidate designed to treat and cure human immunodeficiency virus (HIV) infection. Gritstone bio, Inc. has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
 CEO
 WEBSITEhttps://gritstonebio.com
 INDUSTRYBiotechnology
 EMPLOYEES233

Gritstone Oncology Inc Frequently Asked Questions


What is the ticker symbol for Gritstone Oncology Inc? What does GRTS stand for in stocks?

GRTS is the stock ticker symbol of Gritstone Oncology Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Gritstone Oncology Inc (GRTS)?

As of Wed May 22 2024, market cap of Gritstone Oncology Inc is 91.2 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of GRTS stock?

You can check GRTS's fair value in chart for subscribers.

What is the fair value of GRTS stock?

You can check GRTS's fair value in chart for subscribers. The fair value of Gritstone Oncology Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Gritstone Oncology Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for GRTS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Gritstone Oncology Inc a good stock to buy?

The fair value guage provides a quick view whether GRTS is over valued or under valued. Whether Gritstone Oncology Inc is cheap or expensive depends on the assumptions which impact Gritstone Oncology Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for GRTS.

What is Gritstone Oncology Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed May 22 2024, GRTS's PE ratio (Price to Earnings) is -0.63 and Price to Sales (PS) ratio is 5.83. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. GRTS PE ratio will change depending on the future growth rate expectations of investors.